CMAB007

DRUG3 trials

Sponsors

Shanghai Biomabs Pharmaceutical Co., Ltd., Taizhou Mabtech Pharmaceutical Co.,Ltd

Conditions

Asthma, AllergicChronic Spontaneous UrticariaHealthy Volunteers

Phase 1

The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity

CompletedNCT05897008

Taizhou Mabtech Pharmaceutical Co.,LtdHealthy Volunteers

Start: 2022-02-07End: 2022-09-13Updated: 2023-06-12

Phase 3

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

CompletedNCT03468790

Shanghai Biomabs Pharmaceutical Co., Ltd.Asthma, Allergic

Start: 2018-05-09End: 2021-03-09Updated: 2021-10-11

To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria

RecruitingNCT06365879

Taizhou Mabtech Pharmaceutical Co.,LtdChronic Spontaneous Urticaria

Start: 2024-06-18End: 2026-07-01Target: 392Updated: 2025-11-19

Related Papers

Benefits of CMAB007 in Chinese Patients Having Inadequately Controlled Moderate/Severe Asthma With Increased Total IgE: A Randomized Phase 3 Trial.

2025-11-26